Mesoblast Named Top Long-Term ASX Stock Pick
Mesoblast Limited (MESO) has been identified as one of the best long-term ASX stocks to buy, spotlighting the Australian cell therapy biotech's multi-year investment case. The company's mesenchymal stromal cell platform and regulatory progress underpin the bullish thesis. Key watch points include pipeline milestones